+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Inhaled Antibiotics Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5790622
The global inhaled antibiotics market has grown strongly in recent years. It will grow from $1.46 billion in 2023 to $1.58 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The expansion observed in the historical period can be credited to various factors, including regulatory support and approvals, a transition from systemic to targeted delivery methods, an increase in antibiotic resistance, and a rise in respiratory infections.

The global inhaled antibiotics market is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. Anticipated growth in the forecast period can be attributed to several factors such as increased investments in research and development, a wider range of clinical applications, a growing emphasis on personalized medicine, advancements in drug formulations, and ongoing concerns regarding antibiotic resistance. Key trends expected in this period include sustained innovation in formulations, an approach centered around patients' needs, heightened research in respiratory health, a transition toward targeted therapies, and advancements in drug delivery systems.

The anticipated rise in respiratory diseases is poised to drive the growth of the inhaled antibiotics market. These conditions impair lung and airway function, affecting individuals' breathing. Inhaled antibiotics play a crucial role in enhancing lung function, staving off deterioration, extending periods between exacerbations, and improving the quality of life for patients with conditions like cystic fibrosis. Statistics reported by the Australian Institute of Health and Welfare revealed a notable increase in respiratory disease-related deaths in Australia in 2021, totaling 46,551. Similarly, data from The Lancet in September 2022 showcased a 9.50% rise in new cases of respiratory syncytial virus (RSV) during the 2021 summer, underscoring the escalating incidence of respiratory ailments that directly influences the inhaled antibiotics market.

The escalating demand within hospital settings is anticipated to propel the expansion of the inhaled antibiotics market. Hospitals, dedicated to providing medical care to the ill or injured, rely on inhaled antibiotics for managing respiratory infections. These medications help minimize disruptions to gut microbiota, customize treatment approaches, improve patient adherence, and reduce hospitalization rates. As per information from gov.wales in October 2022, NHS bed occupancy rose to 81.2% in 2021-22, marking an 11.8 percentage point increase from the previous year, indicative of the heightened reliance on healthcare facilities. This surge in hospital demand significantly influences the growth trajectory of inhaled antibiotics.

A prominent trend within the inhaled antibiotics market is the substantial investments directed towards their development. Pharmaceutical giants, exemplified by Enbiotix's $11 million investment in December 2021, are actively funding the development of antibiotics tailored for lung infections. These investments focus on clinical testing for medications like murepavadin and ColiFin, specifically targeting patients with cystic fibrosis (CF). Such initiatives underscore the commitment of major pharmaceutical entities towards advancing treatment options for respiratory ailments.

Innovative products like Breyna are being strategically introduced by major players in the inhaled antibiotics market to drive revenue growth. Breyna, an inhalation aerosol combining formoterol fumarate dihydrate and budesonide, effectively manages symptoms associated with asthma and persistent lung diseases. Viatris Inc., in partnership with Kindeva Drug Delivery L.P., successfully launched Breyna in July 2023. This FDA-approved generic version of AstraZeneca's Symbicort is supplied as a metered-dose inhaler and comes in two strengths, catering to patients' varying needs, reflecting the market's focus on innovation and tailored therapeutic solutions.

In August 2021, Philip Morris International Inc., a US-based tobacco company, acquired OtiTopic for an undisclosed sum. This acquisition aligns with PMI's strategic goal of broadening its portfolio of inhaled therapies and respiratory medication delivery. Utilizing its expertise, scientific knowledge, and inhalation capabilities beyond nicotine, PMI aims to expand its offerings in this domain. OtiTopic, a US-based respiratory drug development company specializing in inhaled antibiotics, now operates under the umbrella of Philip Morris International Inc.

Major companies operating in the inhaled antibiotics market report are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt. Ltd., Precept Pharma Ltd., Luckys Pharma, Novartis AG, Bayer AG, Pfizer Inc., Grifols SA, Vertex Pharmaceuticals Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals, Synspira Therapeutics Inc., AIT Therapeutics Inc., Polyphor AG, Oppilan Pharma Ltd., OptiNose Inc.

North America was the largest region in the inhaled antibiotics market share in 2023. The regions covered in the inhaled antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhaled antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diverse types of inhaled antibiotics are available, including aerosol or metered dose inhalers, dry powder formulations, sprays, and other variations. The metered-dose inhaler (MDI) stands as a frequently utilized device for delivering inhaled respiratory medications. These antibiotics find applications across a spectrum of respiratory conditions like pneumonia, asthma, bronchitis, among others, catering to the needs of hospitals and various other healthcare settings.

This report provides inhaled antibiotics market statistics, including inhaled antibiotics industry global market size, regional shares, competitors with an inhaled antibiotics market share, detailed inhaled antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the inhaled antibiotics industry. This inhaled antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhaled antibiotics market consists of sales of jet nebulizers, ultrasonic nebulizers, mesh inhalers, and soft mist inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Inhaled Antibiotics Market Characteristics3. Inhaled Antibiotics Market Trends and Strategies
4. Inhaled Antibiotics Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Inhaled Antibiotics Market Size and Growth
5.1. Global Inhaled Antibiotics Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Inhaled Antibiotics Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Inhaled Antibiotics Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Inhaled Antibiotics Market Segmentation
6.1. Global Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Aerosol or Metered Dose Inhaler
  • Dry Powder Formulation
  • Spray
  • Other Types
6.2. Global Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pneumonia
  • Asthma
  • Bronchitis
  • Other Applications
6.3. Global Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Other End Users
7. Inhaled Antibiotics Market Regional and Country Analysis
7.1. Global Inhaled Antibiotics Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Inhaled Antibiotics Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Inhaled Antibiotics Market
8.1. Asia-Pacific Inhaled Antibiotics Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Inhaled Antibiotics Market
9.1. China Inhaled Antibiotics Market Overview
9.2. China Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Inhaled Antibiotics Market
10.1. India Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Inhaled Antibiotics Market
11.1. Japan Inhaled Antibiotics Market Overview
11.2. Japan Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Inhaled Antibiotics Market
12.1. Australia Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Inhaled Antibiotics Market
13.1. Indonesia Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Inhaled Antibiotics Market
14.1. South Korea Inhaled Antibiotics Market Overview
14.2. South Korea Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Inhaled Antibiotics Market
15.1. Western Europe Inhaled Antibiotics Market Overview
15.2. Western Europe Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Inhaled Antibiotics Market
16.1. UK Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Inhaled Antibiotics Market
17.1. Germany Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Inhaled Antibiotics Market
18.1. France Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Inhaled Antibiotics Market
19.1. Italy Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Inhaled Antibiotics Market
20.1. Spain Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Inhaled Antibiotics Market
21.1. Eastern Europe Inhaled Antibiotics Market Overview
21.2. Eastern Europe Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Inhaled Antibiotics Market
22.1. Russia Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Inhaled Antibiotics Market
23.1. North America Inhaled Antibiotics Market Overview
23.2. North America Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Inhaled Antibiotics Market
24.1. USA Inhaled Antibiotics Market Overview
24.2. USA Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Inhaled Antibiotics Market
25.1. Canada Inhaled Antibiotics Market Overview
25.2. Canada Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Inhaled Antibiotics Market
26.1. South America Inhaled Antibiotics Market Overview
26.2. South America Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Inhaled Antibiotics Market
27.1. Brazil Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Inhaled Antibiotics Market
28.1. Middle East Inhaled Antibiotics Market Overview
28.2. Middle East Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Inhaled Antibiotics Market
29.1. Africa Inhaled Antibiotics Market Overview
29.2. Africa Inhaled Antibiotics Market, Segmentation by Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Inhaled Antibiotics Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Inhaled Antibiotics Market, Segmentation by End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Inhaled Antibiotics Market Competitive Landscape and Company Profiles
30.1. Inhaled Antibiotics Market Competitive Landscape
30.2. Inhaled Antibiotics Market Company Profiles
30.2.1. Gilead Sciences Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Lupin Limited
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Insmed Inc.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Savara Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Joincare Pharmaceutical Group Industry Co. Ltd.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Global Inhaled Antibiotics Market Competitive Benchmarking32. Global Inhaled Antibiotics Market Competitive Dashboard33. Key Mergers and Acquisitions in the Inhaled Antibiotics Market
34. Inhaled Antibiotics Market Future Outlook and Potential Analysis
34.1 Inhaled Antibiotics Market in 2028 - Countries Offering Most New Opportunities
34.2 Inhaled Antibiotics Market in 2028 - Segments Offering Most New Opportunities
34.3 Inhaled Antibiotics Market in 2028 - Growth Strategies
34.3.1 Market Trend-based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic and Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Analyst
35.6. Copyright and Disclaimer

Executive Summary

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhaled antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for inhaled antibiotics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Report Scope

Markets Covered:

1) By Product Type: Aerosol or Metered Dose Inhaler; Dry Powder Formulation; Spray; Other Types
2) By Application: Pneumonia; Asthma; Bronchitis; Other Applications
3) By End-User: Hospitals; Other End Users

Key Companies Mentioned: Gilead Sciences Inc.; Lupin Limited; Insmed Inc.; Savara Inc.; Joincare Pharmaceutical Group Industry Co. Ltd

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Gilead Sciences Inc.
  • Lupin Limited
  • Insmed Inc.
  • Savara Inc.
  • Joincare Pharmaceutical Group Industry Co. Ltd.
  • Pharmaxis Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Raptor Pharmaceutical Corporation
  • Altan Pharma Limited
  • Cipla Limited
  • Maya Biotech Pvt. Ltd.
  • Medisol Lifescience Pvt. Ltd.
  • Nivon Specialties
  • Sentiss Pharma Pvt. Ltd.
  • Ultratech India Limited
  • Midas Care Pharmaceuticals Pvt. Ltd.
  • Precept Pharma Ltd.
  • Luckys Pharma
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Grifols SA
  • Vertex Pharmaceuticals Inc.
  • Aridis Pharmaceuticals
  • Bayer HealthCare
  • Nektar Therapeutics
  • Parion Sciences Inc.
  • Zambon Group
  • Transave Inc.
  • Alitair Pharmaceuticals
  • Synspira Therapeutics Inc.
  • AIT Therapeutics Inc.
  • Polyphor AG
  • Oppilan Pharma Ltd.
  • OptiNose Inc.

Methodology

Loading
LOADING...